Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMETA: Savolitinib plus Durvalumab vs Sunitinib vs Durvalumab in MET-driven Papillary Renal Cell Carcinoma
2022-503105-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial in papillary renal cell carcinoma (PRCC) comparing Savolitinib plus Durvalumab, Sunitinib monotherapy and Durvalumab monotherapy (3 arms). Primary endpoint: Progression-free survival (primary). Planned start Jun 2024; status: authorised.
02
Drugs
savolitinibdurvalumabsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on 2022-503105-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503105-38-00.